From Drug Benefit News - As the ongoing generics wave begins to peak with recent approvals of generic Boniva (ibandronate) for osteoporosis, Lexapro (escitalopram) for depression and anxiety and Seroquel (quetiapine) for schizophrenia, some insurers are continuing to tweak their generic utilization strategies with increased copay differentials, step edits and generic prescribing incentives while simultaneously considering ways to maximize cost savings from the impending arrival of biosimilars. Read more